What doesn’t kill the brain makes it stronger

	Tweet

Johns Hopkins scientists say that a newly discovered “survival protein” protects the brain against the effects of stroke in rodent brain tissue by interfering with a particular kind of cell death that’s also implicated in complications from diabetes and heart attack.

Reporting in the May 22 advance online edition of Nature Medicine, the Johns Hopkins team says it exploited the fact that when brain tissue is subjected to a stressful but not lethal insult a defense response occurs that protects cells from subsequent insult. The scientists dissected this preconditioning pathway to identify the most critical molecular players, of which a newly identified protein protector – called Iduna—is one.

Named for a mythological Norwegian goddess who guards a tree full of golden apples used to restore health to sick and injured gods, the Iduna protein increased three- to four-fold in preconditioned mouse brain tissue, according to the scientists. 

"Apparently, what doesn’t kill you makes you stronger,” says Valina Dawson, Ph.D., professor of neurology and neuroscience in the Johns Hopkins Institute of Cell Engineering. “This protective response was broad in its defense of neurons and glia and blood vessels – the entire brain. It’s not just a delay of death, but real protection that lasts for about 72 hours.”

The team noted that Iduna works by interrupting a cascade of molecular events that result in a common and widespread type of brain cell death called parthanatos often found in cases of stroke, Parkinson’s Disease, diabetes and heart attack. By binding with a molecule known as PAR polymer, Iduna prevents the movement of cell-death-inducing factor (AIF) into a cell’s nucleus.

In some of the experiments, Dawson and her team exposed mouse brain cells to short bursts of a toxic chemical, and then screened these “preconditioned” cells for genes that turned on as a result of the insult. Focusing on Iduna, the researchers turned up the gene’s activity in the cells during exposure to the toxic chemical that induced preconditioning. Cells deficient in Iduna did not survive, but those with more Iduna did.

In another series of experiments in live mice, the team injected a toxic chemical into the brains of a control group of normal mice and also into a group that had been genetically engineered to produce three to four times the normal amount of Iduna – as if they had been preconditioned. The engineered mice with more Iduna were much less susceptible to brain cell death: They had more functional tissue and markedly reduced stroke damage in their brains. In addition, the Iduna mice were less impaired in their ability to move around in their cages.

“Identifying protective molecules such as Iduna might someday lead to drugs that trigger the brain survival mechanism when people have a stroke or Parkinson’s disease,” says Ted Dawson, M.D., Ph.D., Leonard and Madlyn Abramson Professor in Neurodegenerative Diseases and scientific director of the Johns Hopkins Institute for Cell Engineering.

In research published April 5 in Science Signaling, the Dawsons’ laboratories previously revealed the mechanism that underpins AIF’s pivotal role in parthanatos.

By studying the 3-D structure of AIF, the team first identified the molecular pocket that looked like a potential PAR binding site. They then swapped that region out for a different one to see if it indeed took up PAR. Using HeLa cells in addition to mouse nerve and skin cells, the scientists noted that the AIF with the swapped region did not bind PAR and was not able to move into the nucleus.

The team genetically manipulated neurons so that they didn’t make any AIF, then in some cells added wild-type AIF, and in others added an AIF that did not bind PAR. When those cells were stressed using the “stroke in a dish” technique, the cells with normal AIF died while those with the AIF that could not bind PAR did not, revealing that PAR binding to AIF is required for parthanatos.

“These findings suggest that identifying chemicals that block PAR binding to AIF could be very protective,” says Ted Dawson. “On the other hand, identifying chemicals that mimic the effect of PAR polymer could be novel therapeutic agents that would kill cancers by causing cell death.”

###

Hopkins authors on the Iduna paper, in addition to Valina and Ted Dawson, are Shaida A. Andrabi, HoChul Kang, Yun-Il Lee, Jian Zhang, Zhikai Chi, Andrew B. West, Raymond C. Koehler and Guy G. Poirier. Other authors include Jean-Francios Haince of Centre Hospitalier Universitaire de Quebec.

Hopkins authors on the AIF paper, in addition to Valina and Ted Dawson, are Yingfei Wang, No Soo Kim, HoChul Kang, Karen K. David and Shaida A. Andrabi. Additional authors are Guy G. Poirier and Jean-Francois Haince of the Laval University Medical Research Center.

The Iduna work was supported by the National Institute of Neurological Disorders and Stroke (NINDS), the McKnight Endowment for the Neurosciences and the National Institute of Drug Abuse.

The AIF research was supported by the National Institute of Neurological Disorders and Stroke, American Heart Association and a Canadian Institutes Health Research grant.

###

Contact: Maryalice Yakutchik

443-287-2251
Johns Hopkins Medical Institutions

RELATED STORIES:
Hope for new alcoholism treatment   High salt intake linked to strokes and cardiovascular disease   The changing roles of 2 hemispheres in stroke recovery   Brain stimulation can help partially paralyzed stroke patients regain use of their muscles   Sleep Apnea Linked to Increased Risk of Stroke   Indications of Alzheimer’s Disease May Be Evident Decades Before First Signs of Cognitive Impairment   Study reveals how one form of natural vitamin E protects brain after stroke   More deaths when green doctors place neck stents   New study identifies risk factors in severity of ‘flat head syndrome’ in babies   Contemplative Brain Network Less Complex in Children   Obese dieters’ brain chemistry works against their weight-loss efforts   Brain Swelling Key to Reducing Stroke Fatalities

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]